Semaglutide + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatobiliary Disorders
Conditions
Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
Trial Timeline
Nov 28, 2017 → Mar 20, 2020
NCT ID
NCT03357380About Semaglutide + Placebo
Semaglutide + Placebo is a phase 1 stage product being developed by Novo Nordisk for Hepatobiliary Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT03357380. Target conditions include Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06041217 | Phase 3 | Completed |
| NCT05726227 | Phase 3 | Active |
| NCT05891496 | Phase 3 | Completed |
| NCT05486065 | Phase 2 | Completed |
| NCT04889183 | Phase 3 | Completed |
| NCT04979130 | Approved | Completed |
| NCT04822181 | Phase 3 | Active |
| NCT03842202 | Phase 1 | Completed |
| NCT03548987 | Phase 3 | Completed |
| NCT03357380 | Phase 1 | Completed |
| NCT03086330 | Phase 3 | Completed |
| NCT02692716 | Phase 3 | Completed |
| NCT02970942 | Phase 2 | Completed |
| NCT02906930 | Phase 3 | Completed |
| NCT02827708 | Phase 3 | Completed |
| NCT02773381 | Phase 1 | Completed |
| NCT02557620 | Phase 1 | Completed |
| NCT02305381 | Phase 3 | Completed |
| NCT02212067 | Phase 1 | Completed |
| NCT02161588 | Phase 1 | Completed |
Competing Products
4 competing products in Hepatobiliary Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| Semaglutide + Placebo | Novo Nordisk | Phase 2 | 51 |
| Phosphatidylcholine | Sanofi | Phase 3 | 76 |
| Zimberelimab + Domvanalimab | Arcus Biosciences | Phase 2 | 47 |